Accessibility Menu
 
Celyad Oncology logo

Celyad Oncology

(NASDAQ) CYAD

Current PriceN/A
Market CapN/A
Since IPO (2015)-99%
5 Year-98%
1 Year-70%
1 Month-41%

Celyad Oncology Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$288.00K

Net Income (TTM)

$14.27M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

CYAD News

No articles available.

CYAD: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Celyad Oncology

Industry

Biotechnology

Headquarters

Mont-Saint-Guibert, 1435, BE

CYAD Financials

Key Financial Metrics (TTM)

Gross Margin

-1%

Operating Margin

-36%

Net Income Margin

-35%

Return on Equity

67%

Return on Capital

-3%

Return on Assets

-1%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Short Interest

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$174.00K

Operating Income

$5.86M

EBITDA

$5.69M

Operating Cash Flow

$15.20M

Capital Expenditure

$899.00K

Free Cash Flow

$16.10M

Cash & ST Invst.

$7.00M

Total Debt

$1.06M

Celyad Oncology Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q4 2024YOY CHG

Revenue

$172.00K

N/A

Gross Profit

$169.00K

+136.0%

Gross Margin

98.26%

N/A

Market Cap

N/A

N/A

Market Cap/Employee

N/A

N/A

Employees

35

N/A

Net Income

$2.78M

+89.7%

EBITDA

$2.83M

+89.3%

Quarterly Fundamentals

Name
Q4 2024YOY CHG

Net Cash

$5.24M

-57.1%

Accounts Receivable

$74.00K

-98.0%

Inventory

$0.00

N/A

Long Term Debt

$834.00K

-39.6%

Short Term Debt

$155.00K

-80.2%

Return on Assets

-1.14%

N/A

Return on Invested Capital

-3.38%

N/A

Free Cash Flow

$2.83M

+82.8%

Operating Cash Flow

$2.83M

+82.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IMNNImunon, Inc.
$3.02+2.20%
SQZBSQZ Biotechnologies Company
$0.02-0.41%
REUNReunion Neuroscience Inc.
$1.12-0.89%
AXLAAxcella Health Inc.
$4.58+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
ANNAAleAnna
$7.22+0.91%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.17-0.06%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.72+0.05%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.21-0.06%

Questions About CYAD

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.